Trial Information

Phase II Trial of Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients With Small Primary Tumor

Nephrectomy has become an integral part of the management of patients with metastatic kidney
cancer. Performing nephrectomy in these patients is not without risk, however. The very
real chance of significant metastatic disease progression during the postoperative period or
complication before or during surgery that may prolong postoperative recovery could
potentially delay or prevent the administration of systemic therapy in the postoperative
period. Patient selection for surgery remains critical for success.

Radiofrequency ablation (RFA) is a medical procedure where tumor is ablated using microwave
energy to treat a medical disorder. The benefits of RFA in selected metastatic renal cell
carcinoma patients with small primary tumor (<5 cm) will be evaluated in this Phase I/II
study.